VIOLET

Specialisation

Retina and vitreous

Full title

An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of three different treatment regimens of 2 mg aflibercept administered by intravitreal injections to subjects with diabetic macular edema (DME)

Promoter

Bayer.

Start date

November 2016

End date

April 2017

Researchers

Main: Dr Anniken Burés.